Citius Pharmaceuticals Inc. (NASDAQ: CTXR) announced today that it has entered into a definitive agreement for a registered direct offering of 3,973,510 shares of its common stock (or pre‑funded warrants) and accompanying common warrants to purchase up to an aggregate of 3,973,510 shares. The shares will be sold at a purchase price of $1.51 per share, with the accompanying common warrants exercisable immediately at an exercise price of $1.40 per share.
The offering is priced at‑the‑market under Nasdaq rules and is expected to raise approximately $6.0 million in gross proceeds. Citius plans to use the net proceeds to support the commercial launch of its FDA‑approved immunotherapy LYMPHIR, including milestone, regulatory and other payments, development initiatives for all product candidates, and general corporate purposes.
The transaction follows a series of capital‑raising activities that have brought Citius’s total cash and cash equivalents to $6.09 million as of June 30, 2025, while the company faces a going‑concern warning through September 2025. The new financing is intended to extend liquidity and enable the company to meet the costs associated with LYMPHIR’s launch and ongoing development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.